Probiotics as adjunctive treatment for chronic rhinosinusitis

A randomized controlled trial

Shraddha S. Mukerji, Melissa A. Pynnonen, Hyungjin Myra Kim, Andrew Singer, Mark Tabor, Jeffrey E. Terrell

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: To determine if oral probiotics as adjunctive treatment are more effective than placebo in improving quality of life in patients with chronic inflammatory rhinosinusitis. Design: Prospective, randomized, double-blind, placebo-controlled trial. Methods: A total of 77 patients with chronic inflammatory rhinosinusitis were randomly assigned to receive oral probiotic Lactobacillus rhamnosus R0011 strain (500 million active cells/tablet twice daily) (n = 39) or oral placebo treatment (n = 38) for 4 weeks. Results: In the probiotic group, the mean change from baseline in the SNOT-20 scores was significant at 4 weeks (P = 0.002) but not at 8 weeks (P = 0.37). Rhinological domain improved by 9.3 percent (P = 0.004) in probiotics group but returned to baseline level at 8 weeks. No significant differences were found between the probiotic and placebo groups in mean changes from baseline to 4 weeks (P = 0.79) or from baseline to 8 weeks (P = 0.23). No changes in symptom frequency were noted, either within each group or between treatment groups at 4 and 8 weeks. There was no difference in medication use or side effects between the two study groups. Conclusion: Oral use of the probiotic strain L rhamnosus R0011 did not improve sinonasal quality-of-life scores in patients with chronic inflammatory rhinosinusitis compared with placebo.

Original languageEnglish (US)
Pages (from-to)202-208
Number of pages7
JournalOtolaryngology - Head and Neck Surgery
Volume140
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Probiotics
Randomized Controlled Trials
Placebos
Therapeutics
Quality of Life
Lactobacillus rhamnosus
Tablets

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Surgery

Cite this

Probiotics as adjunctive treatment for chronic rhinosinusitis : A randomized controlled trial. / Mukerji, Shraddha S.; Pynnonen, Melissa A.; Kim, Hyungjin Myra; Singer, Andrew; Tabor, Mark; Terrell, Jeffrey E.

In: Otolaryngology - Head and Neck Surgery, Vol. 140, No. 2, 02.2009, p. 202-208.

Research output: Contribution to journalArticle

Mukerji, Shraddha S. ; Pynnonen, Melissa A. ; Kim, Hyungjin Myra ; Singer, Andrew ; Tabor, Mark ; Terrell, Jeffrey E. / Probiotics as adjunctive treatment for chronic rhinosinusitis : A randomized controlled trial. In: Otolaryngology - Head and Neck Surgery. 2009 ; Vol. 140, No. 2. pp. 202-208.
@article{9b2b72dd55334d3ab72406b20f3d7e92,
title = "Probiotics as adjunctive treatment for chronic rhinosinusitis: A randomized controlled trial",
abstract = "Objective: To determine if oral probiotics as adjunctive treatment are more effective than placebo in improving quality of life in patients with chronic inflammatory rhinosinusitis. Design: Prospective, randomized, double-blind, placebo-controlled trial. Methods: A total of 77 patients with chronic inflammatory rhinosinusitis were randomly assigned to receive oral probiotic Lactobacillus rhamnosus R0011 strain (500 million active cells/tablet twice daily) (n = 39) or oral placebo treatment (n = 38) for 4 weeks. Results: In the probiotic group, the mean change from baseline in the SNOT-20 scores was significant at 4 weeks (P = 0.002) but not at 8 weeks (P = 0.37). Rhinological domain improved by 9.3 percent (P = 0.004) in probiotics group but returned to baseline level at 8 weeks. No significant differences were found between the probiotic and placebo groups in mean changes from baseline to 4 weeks (P = 0.79) or from baseline to 8 weeks (P = 0.23). No changes in symptom frequency were noted, either within each group or between treatment groups at 4 and 8 weeks. There was no difference in medication use or side effects between the two study groups. Conclusion: Oral use of the probiotic strain L rhamnosus R0011 did not improve sinonasal quality-of-life scores in patients with chronic inflammatory rhinosinusitis compared with placebo.",
author = "Mukerji, {Shraddha S.} and Pynnonen, {Melissa A.} and Kim, {Hyungjin Myra} and Andrew Singer and Mark Tabor and Terrell, {Jeffrey E.}",
year = "2009",
month = "2",
doi = "10.1016/j.otohns.2008.11.020",
language = "English (US)",
volume = "140",
pages = "202--208",
journal = "Otolaryngology - Head and Neck Surgery (United States)",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Probiotics as adjunctive treatment for chronic rhinosinusitis

T2 - A randomized controlled trial

AU - Mukerji, Shraddha S.

AU - Pynnonen, Melissa A.

AU - Kim, Hyungjin Myra

AU - Singer, Andrew

AU - Tabor, Mark

AU - Terrell, Jeffrey E.

PY - 2009/2

Y1 - 2009/2

N2 - Objective: To determine if oral probiotics as adjunctive treatment are more effective than placebo in improving quality of life in patients with chronic inflammatory rhinosinusitis. Design: Prospective, randomized, double-blind, placebo-controlled trial. Methods: A total of 77 patients with chronic inflammatory rhinosinusitis were randomly assigned to receive oral probiotic Lactobacillus rhamnosus R0011 strain (500 million active cells/tablet twice daily) (n = 39) or oral placebo treatment (n = 38) for 4 weeks. Results: In the probiotic group, the mean change from baseline in the SNOT-20 scores was significant at 4 weeks (P = 0.002) but not at 8 weeks (P = 0.37). Rhinological domain improved by 9.3 percent (P = 0.004) in probiotics group but returned to baseline level at 8 weeks. No significant differences were found between the probiotic and placebo groups in mean changes from baseline to 4 weeks (P = 0.79) or from baseline to 8 weeks (P = 0.23). No changes in symptom frequency were noted, either within each group or between treatment groups at 4 and 8 weeks. There was no difference in medication use or side effects between the two study groups. Conclusion: Oral use of the probiotic strain L rhamnosus R0011 did not improve sinonasal quality-of-life scores in patients with chronic inflammatory rhinosinusitis compared with placebo.

AB - Objective: To determine if oral probiotics as adjunctive treatment are more effective than placebo in improving quality of life in patients with chronic inflammatory rhinosinusitis. Design: Prospective, randomized, double-blind, placebo-controlled trial. Methods: A total of 77 patients with chronic inflammatory rhinosinusitis were randomly assigned to receive oral probiotic Lactobacillus rhamnosus R0011 strain (500 million active cells/tablet twice daily) (n = 39) or oral placebo treatment (n = 38) for 4 weeks. Results: In the probiotic group, the mean change from baseline in the SNOT-20 scores was significant at 4 weeks (P = 0.002) but not at 8 weeks (P = 0.37). Rhinological domain improved by 9.3 percent (P = 0.004) in probiotics group but returned to baseline level at 8 weeks. No significant differences were found between the probiotic and placebo groups in mean changes from baseline to 4 weeks (P = 0.79) or from baseline to 8 weeks (P = 0.23). No changes in symptom frequency were noted, either within each group or between treatment groups at 4 and 8 weeks. There was no difference in medication use or side effects between the two study groups. Conclusion: Oral use of the probiotic strain L rhamnosus R0011 did not improve sinonasal quality-of-life scores in patients with chronic inflammatory rhinosinusitis compared with placebo.

UR - http://www.scopus.com/inward/record.url?scp=59249084301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59249084301&partnerID=8YFLogxK

U2 - 10.1016/j.otohns.2008.11.020

DO - 10.1016/j.otohns.2008.11.020

M3 - Article

VL - 140

SP - 202

EP - 208

JO - Otolaryngology - Head and Neck Surgery (United States)

JF - Otolaryngology - Head and Neck Surgery (United States)

SN - 0194-5998

IS - 2

ER -